BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...persistence in various organs. However, sGC activator Adempas riociguat...
BioCentury | May 20, 2019
Distillery Therapeutics

Cyclerion's sGC stimulator praliciguat ameliorates NASH in rodents

...IW-1973) in Phase II testing for heart failure and diabetic nephropathy. Bayer AG markets Adempas riociguat...
BioCentury | Feb 22, 2019
Politics & Policy

China releases list of rare disease drugs with reduced VAT

...bosentan and Opsumit macitentan from Actelion Ltd., now part of Johnson & Johnson (NYSE:JNJ); Adempas riociguat...
BioCentury | Jan 18, 2019
Company News

Bayer to increase patient access to specialty drugs with ZappRx digital platform

...founder and CEO Zoë Barry did not disclose financial details. Bayer markets sGC activator Adempas riociguat...
BioCentury | Jan 16, 2019
Company News

Bayer to increase patient access to specialty drugs with ZappRx digital platform

...founder and CEO Zoë Barry did not disclose financial details. Bayer markets sGC activator Adempas riociguat...
BioCentury | Sep 12, 2016
Clinical News

Adempas riociguat: Final Phase IIIb data

...endothelin receptor antagonist in the open-label, international Phase IIIb RESPITE trial showed that thrice-daily oral Adempas...
...as WHO functional class III decreased to 52% at week 24 from 100% at baseline. Adempas...
...AG (Xetra:BAYN), Leverkusen, Germany Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Adempas riociguat ( BAY 63-2521...
BioCentury | Jul 11, 2016
Clinical News

Adempas riociguat regulatory update

...EMA’s CHMP recommended against the use of Adempas riociguat from Bayer to treat pulmonary hypertension associated...
...Phase II RISE-IIP trial due to safety issues. The study’s IDMC observed that patients receiving Adempas...
...AG (Xetra:BAYN), Leverkusen, Germany Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Adempas riociguat ( BAY 63-2521...
BioCentury | Jul 11, 2016
Finance

Shedding red

.../ Merck & Co. Inc. (NYSE:MRK) Bayer stops the Phase IIb RISE-IIP trial of Adempas riociguat...
...hypertension associated with idiopathic interstitial pneumonia (PH-IIP) after an independent DMC "observed that patients receiving riociguat...
BioCentury | May 23, 2016
Clinical News

Adempas riociguat: Phase IIb discontinued

...Phase IIb RISE-IIP trial in 147 patients after the study’s IDMC observed that patients receiving Adempas...
...identify a cause or common feature among patients who died, though many patients in the Adempas...
...AG (Xetra:BAYN), Leverkusen, Germany Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Adempas riociguat ( BAY 63-2521...
BioCentury | May 13, 2016
Clinical News

Bayer halts Adempas trial on safety concerns

...Bayer AG (Xetra:BAYN) said it stopped the 147-patient Phase IIb RISE-IIP study of Adempas riociguat to...
...associated with idiopathic interstitial pneumonia (PH-IIP) after the study's independent DMC "observed that patients receiving riociguat...
...identify a cause or common feature among patients who died, though many patients in the Adempas...
Items per page:
1 - 10 of 64